tiprankstipranks
Athira Pharma (ATHA)
NASDAQ:ATHA
US Market
Holding ATHA?
Track your performance easily

Athira Pharma (ATHA) Income Statement

543 Followers

Athira Pharma Income Statement

Last quarter (Q3 2024), Athira Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Athira Pharma's net income was $-28.74M. See Athira Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-----$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 111.69M$ 126.94M$ 88.86M$ 64.02M$ 20.00M$ 4.70M
Operating Income
$ -114.35M$ -125.47M$ -104.02M$ -64.02M$ -20.00M$ -4.70M
Net Non Operating Interest Income Expense
---$ 334.00K$ -243.00K$ -295.00K
Other Income Expense
$ 11.77M$ 9.27M$ -6.78M$ -334.00K$ 1.28M$ -171.00K
Pretax Income
$ -109.19M$ -117.67M$ -95.64M$ -63.69M$ -21.28M$ -5.16M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -109.45M$ -117.67M$ -95.64M$ -55.27M$ -19.95M$ -5.06M
Basic EPS
$ -2.85$ -3.09$ -2.53$ -1.49$ -1.67$ -0.82
Diluted EPS
$ -2.85$ -3.09$ -2.53$ -1.49$ -1.67$ -0.82
Basic Average Shares
$ 153.32M$ 38.02M$ 37.73M$ 36.92M$ 11.97M$ 6.19M
Diluted Average Shares
$ 153.32M$ 38.02M$ 37.73M$ 36.92M$ 11.97M$ 6.19M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 50.72M$ 126.94M$ 88.86M$ 64.02M$ 20.00M$ 4.70M
Net Income From Continuing And Discontinued Operation
$ -109.19M$ -117.67M$ -95.64M$ -54.85M$ -19.95M$ -5.16M
Normalized Income
$ -76.99M----$ -5.09M
Interest Expense
-----$ 346.00K
EBIT
$ -81.94M$ -126.94M$ -88.86M$ -55.19M$ -19.59M$ -4.82M
EBITDA
$ -81.03M$ -125.97M$ -88.01M$ -54.71M$ -19.59M$ -4.82M
Currency in USD

Athira Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis